摘要
目的 :观察新型非甾体消炎止痛药怡美力治疗类风湿关节炎和骨关节炎的疗效和不良反应。方法 :80例类风湿关节炎病人随机分为治疗组 5 0例 ,对照组 30例。 40例骨关节炎病人分为治疗组 2 0例 ,对照组 2 0例。治疗组服怡美力 10 0mg ,po ,bid× 4wk ;对照组服双氯芬酸钠 2 5mg ,po,tid× 4wk。 结果 :在治疗组中类风湿关节炎组和骨关节炎组的疗效分别为 84%和80 % ,对照组为 83.33 %和 80 % ,两组无显著差异 (P >0 .0 5 )。不良反应发生率治疗组和对照组分别为 13.75 %和 30 % ,治疗组明显低于对照组 (P <0 .0 5 )。结论 :怡美力是一种安全有效的新型非甾体消炎止痛药。
OBJECTIVE:To observe the efficacy and safety of the new NSAIDs nimesulide in treating rheumatoid arthritis and osteoarthritis. METHOD:Eighty patients with rheumatoid arthritis were randomly divided into 2 groups, 50 patients of treatment group were treated with nimesulid 100mg, po, tid, and 30 patients of control group were treated with diclofenac sodium 25mg, po, tid. Forty patients with osteoarthritis were also divided into 2 groups, 20 patients were treated with nimesulide 100mg, po, tid, and the other patients were treated with diclofenac sodium 25mg, po, tid.RESULTS:The efficacy rates of nimesulide and diclofenac sodium in rheumatoid arthritis and osteoarthritis group were 84.00%, 80.00% and 83.33%, 80.00% ( P <0.05). The rates of adverse reaction were respectively 13.75% and 30%. The rates of adverse reaction of nimesulide was lower than diclofenac sodium ( P <0.05).CONCLUSION:Nimesulide is efficacious and safe to treat rheumatoid arthritis and osteoarthritis.
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2002年第3期241-243,共3页
Chinese Journal of Modern Applied Pharmacy
